Human induced pluripotent stem cells: A new source for brown and white adipocytes

Anne-Laure Hafner, Christian Dani

Abstract
Mesenchymal stem cells (MSCs) derived from human induced pluripotent stem cells (hiPSCs) provide a novel source for generating adipocytes, thus opening new avenues for fundamental research and clinical medicine. We present the adipogenic potential of hiPSCs and the various methods to derive hiPSC-MSCs. We discuss the main characteristic of hiPSC-MSCs, which is their low adipogenic capacity as compared to adult-MSCs. Finally, we propose several hypotheses to explain this feature, underlying a potential critical role of the micro-environment. We favour the hypothesis that the range of factors or culture conditions required to induce adipocyte differentiation of MSCs derived from adult tissues and from embryonic-like cells could differ.

INTRODUCTION
Mesenchymal stem cells (MSCs) derived from human induced pluripotent stem cells (hiPSCs) provide a novel source for generating adipocytes. hiPSC-MSCs satisfy the minimal criteria for defining MSCs proposed by the International Society for Cellular Therapy, i.e., express certain cell surface markers, adhere to tissue culture plastics and exhibit differentiation towards osteogenic, chondrogenic and adipogenic lineages. However, hiPSC-MSCs have also been referred to as MSC-like, mesenchymal progenitors or fibroblast-like cells by different authors, including us, because hiPSC-MSCs are not identical to MSCs isolated from adult tissues, as we will discuss. For simplicity, we use the general term MSCs in this review. We present hiPSCs as a unique source of adipocytes and we discussed their therapeutic capacities for obesity and lipodystrophy diseases. Then, we described the main approaches to derive human induced pluripotent stem cell-mesenchymal stem cells (hiPSC-MSCs). Finally, we underlined the low adipogenic capacity of hiPSC-MSCs compared to adult-MSCs and proposed several hypothesis to explain this feature.
coexist, i.e., brown and white adipose tissues, which are both involved in the energy balance while having opposite functions. White adipose tissue (WAT) is mainly involved in energy storage and mobilization in the form of triglycerides. In contrast, brown adipose tissue (BAT) burns fat and is specialized in energy expenditure. BAT is a key thermogenic organ since brown adipocytes convert nutrients into heat by uncoupling respiration from ATP synthesis. BAT implants were recently shown to improve the metabolic conditions in obese mice and to restore normoglycemia and glucose tolerance in streptozotocin-induced diabetic mice[2]. These recent findings offer promising prospects for basic research and clinical medicine-increasing energy expenditure via recruitment of brown adipocyte progenitors could be a valuable therapeutic approach to counteract obesity and its associated metabolic complications. However, BAT represents a minor fraction of the adipose tissue in humans, is found throughout the body and disappears from most areas with age, persisting only around deeper organs[3]. Human BAT is hard to isolate in this regard, so an alternative cellular source is required to generate brown adipocytes.

Congenital or acquired lipodystrophies result from the loss, degeneration or misdistribution of white adipose tissue, leading to diabetes, severe defects in lipid homeostasis and ectopic fat accumulation. Transplantation of white adipose tissue in a lipoatrophy mouse model has been shown to improve the metabolic parameters[4]. Therefore, isolation of hiPSCs-MSCs differentiating into brown and white adipocytes could provide an unlimited source of adipocytes for autologous cell-based therapy to treat obesity and lipodystrophy diseases.

Differentiation of iPSCs into MSCs, and then into adipocytes, also offers a unique opportunity to determine adipocyte properties according to their embryonic origins, but this issue has yet to be investigated in humans. Indeed, individual white adipose tissue depots are not equivalent, as functional differences have been reported in mice and humans[5]. These distinct properties of individual adipose tissue depots could play a role in obesity-related complications and might explain why the spread of only certain depots is associated with severe metabolic disorders. It has also been observed that the different fat depots are not altered in a similar manner in genetic- and drug-induced lipodystrophies[6]. These regional differences were conserved during in vitro propagation and adipocyte differentiation of MSCs, strongly suggesting that MSCs from different fat depots are indeed inherently different[7]. Recent published data, including ours, suggested that MSC embryonic origins could play a role in these intrinsic differences. Surprisingly little is known about the developmental origin of adipocytes in rodents, and nothing is known in humans. Gesta et al[8] compared gene expression profiles of intra-abdominal and sub-cutaneous adipose tissues in mice and found major differences in the expression of several genes involved in embryonic development and pattern specification. We recently demonstrated that subsets of adipocytes have mesodermic and neuroectodermic origins depending on the location of adipose tissue depots in mouse and quail[9,10]. These data are in full agreement with the demonstration of Takashima et al[11] that MSCs originate both from mesoderm and neuroectoderm. Interestingly, the potential of neuro- and meso-derived MSCs to differentiate and participate in tissue repair differs depending on the embryonic origin[12].

**DIFFERENTIATION OF HUMAN-INDUCED PLURIPOTENT STEM CELLS INTO ADIPOCYTES**

Differentiation of hiPSCs offers a unique opportunity to purify human MSCs for the purpose of generating brown and white adipocytes, as well as adipocytes of different embryonic origins from the same patients’ somatic cells. Following the pioneer work of Yamakawa’s group on the generation of iPSCs by reprogramming human fibroblasts[13], the capacity of hiPSCs to generate functional adipocytes was first reported by Nakao’s group. The authors showed that hiPSCs have an adipogenic potential comparable to human embryonic stem cells. Interestingly, hiPSC-adipocytes can maintain their functional properties for several weeks after transplantation into nude mice[14,15]. These data revealed that hiPSC-adipocytes could potentially be used to correct metabolic parameters in patients. In these experiments, differentiated hiPSCs, but not MSCs, were transplanted into mice. Indeed, hiPSC-differentiated cultures are enriched with adipocytes after adipogenic induction, but also contain several other cell types that are undesirable for transplantation, including immature neural cells and undifferentiated iPSCs that can form teratomas several weeks after transplantation. As indicated by Noguchi and colleagues, transplantation of mature adipocytes alone results in graft loss that could be improved by transplanting adipocyte progenitors[16]. Therefore, purification of hiPSC-MSCs with a high adipogenic capacity is required prior to an hiPSC-based therapeutic approach. Nishio et al[10] developed a procedure to generate functional brown adipocytes at a high frequency from hiPSC using a hematopoietic cocktail to induce hiPSC differentiation. Remarkably, hiPSC-brown adipocytes were able to improve glucose tolerance after transplantation in mice. This report established a link between brown adipocytes and hematopoietic cells, and indicated that hiPSCs could potentially be used to generate brown adipocytes with therapeutic properties. As recently reported, we designed a procedure to derive MSCs with a capacity to differentiate into both brown and white adipocytes[17]. In this latter study, the use of small molecules during hiPSC differentiation revealed that TGFβ and retinoic acid pathways regulate the generation of MSC subtypes having a brown or white adipogenic potential, respectively. Differentiation of hiPSCs offers the opportunity to characterize the earliest steps of adipogenesis and identify signalling pathways regulating brown and white fat cell lineages. However, as discussed below,
hiPSC-derived MSCs have a low potential to differentiate into adipocytes compared to hMSCs derived from adult adipose tissue.

ADIPOGENIC CAPACITY OF hiPSC-DERIVED MSCS

Chen et al. [18] first underlined the limited capacity of hiPSC-MSCs to undergo adipocyte differentiation, a feature that has often been observed by authors but not always highlighted. Ahfeldt et al. [19] were able to generate pure brown or white adipocytes from hiPSCs, but only following genetic modification of MSCs. These artificially programmed hMSCs are of great interest from a therapeutic standpoint, but cannot be applied to investigate ontogenesis of human adipocytes. The fact that MSCs must be transduced with adipogenesis master genes clearly illustrates the low adipogenic potential of hiPSC-derived MSCs. This low adipogenic potential is illustrated in Figure 1. As shown, transduction of hiPSC-MSCs with a vector expressing an adipogenic gene, such as C/EBPb LAP, dramatically enhanced the MSC adipogenic potential, as monitored with the FABP4 adipogenic gene expression, but still at a lower level compared to MSCs derived from adipose tissue, also named adipose-derive stem cells (ASCs). Interestingly, some authors claim that the low differentiation capacity is limited to adipogenesis since hiPSC- and hESC-MSCs are able to differentiate towards chondrogenic and osteogenic lineages at high levels[20-22]. MSCs are abundant in adipose tissue, can be easily harvested using liposuction and have a considerable expansion potential ex vivo, particularly when isolated from young donors[23]. Adipose tissue derived MSCs are currently being investigated in autologous transplantations to improve revascularization and tissue perfusion in ischemic limbs[24-26]. Results so far suggest that the efficiency of adipose tissue-MSCs in regenerative medicine could rely more on their cytokine secretory functions and potential use as immunomodulators than on their differentiation potential[27]. The therapeutic potential of MSCs derived from hiPSCs and from human adipose tissue should therefore now be carefully compared.

In recent years, various groups have successfully derived MSCs from hESC and hiPSC using a range of methods. There are two main approaches to differentiate pluripotent stem cells into MSCs (Figure 2).

One strategy involves embryoid body (EB) formation. In this approach, suspension cultures allow pluripotent stem cells to form 3-dimensional structures called EB (Figure 2A). This step models the in vitro embryonic development with the commitment of cells into the three primary germ layers. The duration of this stage may range from 7 to 14 d. EBs are then seeded onto culture dishes and, after a proliferation step, outgrowth cells are maintained in a mesenchymal culture medium. Subsequently, adherent cells display a fibroblast-like morphology and acquire specific MSC markers after se-
MSCs were derived from hiPSCs following (A) or not (B) embryoid body formation. Alternatively, hiPSCs were maintained in co-culture with murine stromal cells, and then MSCs were derived following selection of CD73-positive cells (C). MSCs: Mesenchymal stem cells; hiPSCs: Human induced pluripotent stem cells.

Figure 2  Mesenchymal stem cell derivation strategies. MSCs were derived from hiPSCs following (A) or not (B) embryoid body formation. Alternatively, hiPSCs were maintained in co-culture with murine stromal cells, and then MSCs were derived following selection of CD73-positive cells (C). MSCs: Mesenchymal stem cells; hiPSCs: Human induced pluripotent stem cells.

Serial passages[28,29]. An alternative strategy involves direct differentiation of pluripotent stem cells without the EB step (Figure 2B). Pluripotent stem cells are dissociated into single-cell suspensions and then maintained in mesenchymal medium for several weeks. The resulting cell cultures are enriched for MSCs through serial cell passaging[30]. Another version of this protocol relies on the spontaneous differentiation of pluripotent stem cells into MSCs[31]. Different research groups have developed additional steps to improve this method. For instance, before single-cell suspension, hiPSCs are committed towards MSC differentiation via treatment with small molecules, such as inhibitors of the TGFβ pathway[32]. Using small molecules with the EB method has been shown to promote the generation of two MSC subtypes having a selective potential towards brown and white adipocyte lineages[33]. Growing hiPSCs on a fibrillar-collagen matrix has also been shown to improve their differentiation into MSCs[34]. Coculture of pluripotent stem cells with murine stromal cells, followed by the selection of CD73-positive cells[35], is another way to derive MSCs (Figure 2C). Interestingly, MSCs from mesoderm or from neuroectoderm origins can be derived depending on the stromal cells used[36,37]. Finally, MSCs derived from different hiPSC lines generated from different donors, or from the same hiPSC clone using different derivation approaches, have the same adipogenic features[30,31]. MSC adipogenic characteristics are therefore not dependent on the derivation method used.

Several hypotheses could be put forward to explain the low hiPSC-MSC adipogenic capacity compared to adult MSCs. Interestingly, the low differentiation potential is not restricted to hiPSC-MSCs since MSCs derived from human embryonic stem cells (hESCs) display the same feature, thus ruling out the possibility that the low hiPSC-MSC adipogenic capacity could be due to the reprogramming process or to an epigenetic mechanism. The fact that hiPSCs generated from adipose-derived stem cells or from neural stem cells displayed a similar adipogenic capacity is in agreement with this hypothesis[37]. One possibility is that the criteria to identify hiPSC-MSCs and adult MSCs could differ. For instance, individual cell surface markers used to characterize MSCs are also expressed by non-MSCs such as by fibroblasts[36]. Therefore, it could be important to select hiPSC-MSCs based on the co-expression of several mesenchymal markers and not on CD73 expression only. We favour the hypothesis that the range of factors or culture conditions required to induce adipocyte differentiation of MSCs derived from adult tissues and from embryonic-like cells could differ. The low hiPSC-MSC adipogenic capacity is a reminiscence of an earlier observation reported by Han et al[37]. The authors observed that epididymal adipose tissue, which undergoes postnatal development in mouse, is composed of multipotent progenitor cells that meet the MSC criteria but lack an adipogenic capacity in vitro. In contrast to cells derived from other fat pads, epididymal fat cells require a three-dimensional culture conditions and a different micro-environment to undergo differentiation. These results underline that the micro-environment has a critical role in differentiation but could differ for adult and embryonic-like cells. We have observed that hiPSCs can generate nice adipocyte colonies when MSCs are not derived but are maintained in an iPSC environment. As shown in Figure 3, adipocytes are close to non-adipose cells. We have observed that hiPSC-MSCs can generate nice adipocyte colonies when MSCs are not derived but are maintained in an iPSC environment. As shown in Figure 3, adipocytes are close to non-adipose cells. We have observed that hiPSC-MSCs can generate nice adipocyte colonies when MSCs are not derived but are maintained in an iPSC environment. As shown in Figure 3, adipocytes are close to non-adipose cells.

CONCLUSION

The potential of hiPSCs to generate MSCs having an adipogenic capacity represents a powerful cellular model for studying brown and white adipocyte ontogenesis and
comparing the properties of adipocytes derived from mesoderm or neuroectoderm. This also provides a basis for investigating factors involved in the recruitment of MSCs having different potentials in normal and pathological contexts.

From a clinical standpoint, many issues have to be resolved before using hiP-MSCs in cell-based therapeutic strategies for obesity and lipodystrophy diseases. However, the differentiation of iPSCs towards the adipogenic lineage offers a unique opportunity to purify white and brown adipocytes from patients, which could lead to the development of autologous transplantation procedures to treat obese and lipodystrophic patients. It would be essential to determine the factors underlying the low adipogenic capacity of hiP-MSCs. They are functionally distinct from adult hMSCs and the challenge will be to determine the cellular and molecular events necessary to prime hiPSCs towards the adipogenic lineage at a high level.

REFERENCES

1. Bourin P, Bunnell BA, Castella L, Dominici M, Kats AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytoteraphy 2013; 15: 641-648 [PMID: 23570660 DOI: 10.1016/j.jcyt.2013.02.006]

2. Gunawardana SC, Piston DW. Reversal of type 1 diabetes in mice by brown adipose tissue transplantation. Diabetes 2012; 61: 674-662 [PMID: 22315305 DOI: 10.2337/db11-0510]

3. Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab 2010; 11: 253-256 [PMID: 20374956 DOI: 10.1016/j.cmet.2010.03.004]

4. Garrivolo O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-278 [PMID: 10865352 DOI: 10.1172/JCI9091]

5. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131: 242-256 [PMID: 17956727]

6. Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011; 96: 3313-3325 [PMID: 21865368 DOI: 10.1210/jc.2011-1199]

7. Macotela Y, Emanuelli B, Moro MA, Gesta S, Schulz TJ, Tseng YH, Kahn CR. Intrinsic differences in adipocyte precursor cells from different white fat depots. Diabetes 2012; 61: 1691-1699 [PMID: 22996050 DOI: 10.2337/db11-1753]

8. Gesta S, Blüher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, Boucher J, Lewis C, Kahn CR. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA 2006; 103: 6676-6681 [PMID: 16617105]

9. Billon N, Iannarelli P, Monteiro MC, Glavieux-Pardanaud C, Richardson WD, Kessaris N, Dani C, Dupin E. The generation of adipocytes by the neural crest. Development 2007; 134: 2283-2292 [PMID: 17507398 DOI: 10.1242/dev.002642]

10. Billon N, Dani C. Developmental origins of the adipocyte lineage: new insights from genetics and genomics studies. Stem Cell Rev 2012; 8: 55-66 [PMID: 21365256 DOI: 10.1007/s12015-011-9242-x]

11. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, Nishikawa S. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007; 129: 1377-1386 [PMID: 17604725 DOI: 10.1016/j.cell.2007.04.028]

12. Leucht P, Kim JB, Amanta RA, James AW, Girod S, Helms JA. Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 2008; 135: 2845-2854 [PMID: 18635558 DOI: 10.1242/dev.023788]

13. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872 [PMID: 18034508 DOI: 10.1016/j.cell.2007.11.019]

14. Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, Takahashi K, Homma K, Oyamada N, Inuzuka M, Sonoyama T, Ebihara K, Tomura N, Itoh H, Suemori H, Nakatsuji N, Okano H, Yamanaka S, Nakao K. Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. FEBS Lett 2009; 583: 1029-1033 [PMID: 19250937 DOI: 10.1016/j.febslet.2009.02.031]

15. Noguchi M, Hosoda K, Nakane M, Mori E, Nakao K, Taura D, Yamamoto Y, Kusakabe T, Sone M, Sakurai H, Fujiyama J, Ebihara K, Nakao K. In vitro characterization and engrafment of adipocytes derived from human induced pluripotent stem cells and embryonic stem cells. Stem Cells Dev 2013; 22: 2895-2905 [PMID: 23750558 DOI: 10.1089/scd.2013.0113]

16. Nishio M, Yoneshiro T, Nakahara M, Suzuki S, Saeki K, Hasegawa M, Kawai Y, Akatsu H, Umezawa A, Yasuda K, Tobe K, Yuo A, Kubota K, Saito M, Saeki K. Production of functional classical brown adipocytes from human pluripotent stem cells using specific hemopoietin cocktail without gene transfer. Cell Metab 2012; 16: 394-406 [PMID: 22958922 DOI: 10.1016/j.cmet.2012.08.001]

17. Mohsen-Kanson T, Hafner AL, Wdziekonski B, Takashima Y, Villaggio P, Carrière A, Svensson M, Bagnis C, Chignon-Sicard B, Svensson PA, Castella L, Smith A, Dani C. Differentiation of human induced pluripotent stem cells into brown and white adipocytes: role of Pax3. Stem Cells 2014; 32: 1459-1467 [PMID: 24302443 DOI: 10.1002/stem.1607]

18. Chen YS, Pleakeanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med 2012; 1: 83-95 [PMID: 23197756 DOI: 10.9966/sctm.2011-0022]

19. Alfredt T, Schinzel RT, Lee YK, Hendrickson D, Kaplan A, Lum DH, Camahort R, Xia F, Shay J, Rhee EP, Claire CB, Deo RC, Shen T, Lau FH, Cowley A, Mower G, Al-Siddiqi H, Nahrendorf M, Musunuru K, Gerszten RE, Rinn JL, Cowan CA. Programming human pluripotent stem cells into white and brown adipocytes. Nat Cell Biol 2012; 14: 209-219 [PMID: 22246346 DOI: 10.1038/ncb2411]

20. Xu C, Jiang J, Sottile V, McWhir J, Lebkowski J, Carpenter MK. Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth. Stem Cells 2004; 22: 972-980 [PMID: 15536188 DOI: 10.1634/stemcells.22-6-972]

21. Boyd NL, Robbins KR, Dhara SK, West FD, Sice SL. Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. Tissue Eng Part A 2009; 15: 1897-1907 [PMID: 19196444 DOI: 10.1089/teng.2008.0351]

22. Karlsson C, Emanuelli K, Wessberg F, Kajic J, Axell MZ, Eriksson PS, Lindahl A, Hyllner J, Strehl R. Human embryonic stem cell-derived mesenchymal progenitors—potential in regenerative medicine. Stem Cell Res 2009; 3: 39-50 [PMID: 19515621 DOI: 10.1016/j.scr.2009.05.002]

23. Rodriguez AM, Pianzi D, Dechesne CA, Turc-Carel C, Kurzenne JY, Wdziekonski B, Villaggio A, Bagnis C, Breitmayer JP, Groux H, Alhagud C, Dani C. Transplantation of a multipotent cell population from human adipose tissue in...
duces dystrophin expression in the immunocompetent mdx mouse. J Exp Med 2005; 201: 1397-1405 [PMID: 15867092 DOI: 10.1084/jem.20042224]

24 Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebese B, Poyrafitte JA, Fleury S, Gadeloerge M, Taurand M, Dupuis-Coronas S, Leobon B, Castella L. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014; 16: 245-257 [PMID: 24438903 DOI: 10.1016/j.jcyt.2013.11.011]

25 Castella L, Planat-Benard V, Laharrague P, Cousin B. Adipose-derived stromal/stem cells: Their identity and uses in clinical trials, an update. World J Stem Cells 2011; 3: 25-33 [PMID: 21607134 DOI: 10.2425/wjsc.v3.i4.25]

26 Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillant-Barreau C, Duriez M, Tedgui A, Levy B, Piccaud L, Castella L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004; 109: 656-663 [PMID: 14734516 DOI: 10.1161/01.CIR.0000114522.38265.61]

27 Gimble JM, Nuttall ME. Adipose-derived stromal/stem cells (ASC) in regenerative medicine: pharmaceutical applications. Curr Pharm Des 2011; 17: 332-339 [PMID: 21375497 DOI: 10.2174/138161211795164220]

28 Brown SE, Tong W, Krebsbach PH. The derivation of mesenchymal stem cells from human embryonic stem cells. Cells Tissues Organs 2009; 189: 256-260 [PMID: 18728355 DOI: 10.1159/000151746]

29 Lee EJ, Lee HN, Kang HJ, Kim KH, Hur J, Cho HJ, Lee J, Chung HM, Cho J, Cho MY, Oh SK, Moon SY, Park VB, Kim HS. Novel embryoid body-based method to derive mesenchymal stem cells from human embryonic stem cells. Tissue Eng Part A 2010; 16: 705-715 [PMID: 19895342 DOI: 10.1089/ten.tea.2008.0596]

30 Hynes K, Menicanin D, Mrozik Z, Gronthos S, Bartold PM. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells Dev 2014; 23: 1084-1096 [PMID: 24367908 DOI: 10.1089/scd.2013.0111]

31 Diederichs S, Tuan RS. Functional comparison of human-induced pluripotent stem cell-derived mesenchymal cells and bone marrow-derived mesenchymal stromal cells from the same donor. Stem Cells Dev 2014; 23: 1594-1610 [PMID: 24625206 DOI: 10.1089/scd.2013.0477]

32 Liu Y, Goldberg AJ, Dennis JE, Gronowicz GA, Kuhn LT. One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. PloS One 2012; 7: e33225 [PMID: 22457746 DOI: 10.1371/journal.pone.00033225]

33 Barberi T, Willis LM, Socci ND, Studer L. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2005; 2: e161 [PMID: 15971941 DOI: 10.1371/journal.pmed.0020161]

34 Jiang X, Gevey Y, McKeown SJ, Bronner-Fraser M, Lutsko C, Lawlor ER. Isolation and characterization of neural crest stem cells derived from in vitro-differentiated human embryonic stem cells. Stem Cells Dev 2009; 18: 1059-1070 [PMID: 19099373 DOI: 10.1089/scd.2008.0362]

35 Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA, Slukvin II. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010; 7: 718-729 [PMID: 21112566 DOI: 10.1016/j.stem.2010.11.011]

36 Boxall SA, Jones E. Markers for characterization of bone marrow multipotent stromal cells. Stem Cells Int 2012; 2012: 975871 [PMID: 2266272 DOI: 10.1155/2012/975871]

37 Han J, Lee JE, Jin J, Lim JS, Oh N, Kim K, Chang SI, Shibuya M, Kim H, Koh GY. The spatiotemporal development of adipose tissue. Development 2011; 138: 5027-5037 [PMID: 22026034 DOI: 10.1242/dev.067686]

P-Reviewer: Chen LY, Zhang Q. S-Editor: Song XX. L-Editor: A E-Editor: Lu YJ.
